EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE


facebook twitter youtube
News archive
Recent news

MPE, in collaboration with other patient organisations, is conducting a project to analyse legal agreements of pharmaceutical companies with patient advocates. The project will make suggestions for simpler, more understandable agreements that would sufficiently reflect and protect the interests of both parties.







Recent news

» Daratumumab becomes the first FDA-approved treatment for patients with newly diagnosed light chain (AL) amyloidosis

» Watch the webinar on ASH 2020 myeloma and AL amyloidosis highlights

Leave a Reply

Your email address will not be published. Required fields are marked *

I accept the Privacy Policy * for Click to select the duration you give consent until.